Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 4,153 Shares of Stock

by · The Markets Daily

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) COO Kristen Oelschlager sold 4,153 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $35.95, for a total transaction of $149,300.35. Following the completion of the sale, the chief operating officer directly owned 13,356 shares in the company, valued at $480,148.20. This trade represents a 23.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Trading Up 3.1%

Castle Biosciences stock traded up $1.09 during mid-day trading on Monday, hitting $36.65. The company’s stock had a trading volume of 377,209 shares, compared to its average volume of 397,430. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04. The company has a 50 day moving average of $32.49 and a 200-day moving average of $26.27. Castle Biosciences, Inc. has a one year low of $17.72 and a one year high of $44.28. The stock has a market cap of $1.12 billion, a PE ratio of -55.53 and a beta of 0.94.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The firm had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. On average, research analysts anticipate that Castle Biosciences, Inc. will post -1.29 EPS for the current year.

Institutional Trading of Castle Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of CSTL. BlackRock Inc. purchased a new position in shares of Castle Biosciences during the second quarter worth $78,513,000. Summit Partners Public Asset Management LLC grew its position in Castle Biosciences by 164.7% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock worth $41,184,000 after purchasing an additional 658,725 shares during the period. Jefferies Financial Group Inc. purchased a new position in shares of Castle Biosciences during the 2nd quarter valued at about $15,440,000. Renaissance Technologies LLC lifted its holdings in shares of Castle Biosciences by 8.1% in the 1st quarter. Renaissance Technologies LLC now owns 532,800 shares of the company’s stock valued at $13,080,000 after buying an additional 39,700 shares during the period. Finally, AIGH Capital Management LLC acquired a new position in shares of Castle Biosciences in the 2nd quarter valued at about $13,001,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Roth Capital assumed coverage on shares of Castle Biosciences in a report on Wednesday, June 24th. They issued a “buy” rating and a $40.00 price target on the stock. Wall Street Zen upgraded shares of Castle Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 26th. Robert W. Baird set a $36.00 target price on shares of Castle Biosciences in a research report on Friday, July 31st. BTIG Research raised their target price on shares of Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, Weiss Ratings raised shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Read Our Latest Report on Castle Biosciences

About Castle Biosciences

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to provide personalized information for patients with cancer and other serious diseases. Its products analyze biological characteristics in tissue samples to help physicians assess disease risk, guide treatment decisions and support patient management.

The company’s portfolio includes diagnostic tests for skin cancers, such as DecisionDx-Melanoma for assessing metastatic risk in patients with cutaneous melanoma and DecisionDx-SCC for evaluating metastatic risk in certain cases of cutaneous squamous cell carcinoma.

Featured Articles